Previous 10 | Next 10 |
SAN DIEGO , Dec. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, will be presented today at the 2019 San Antonio Breast Cancer Symposium (SABCS)....
Halozyme (NASDAQ: HALO ) prices its private offering of $400M of 1.25% Convertible Senior Notes due 2024 at par. The initial conversion rate is 41.9208 (~$23.85/common share). More news on: Halozyme Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SAN DIEGO , Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of $400.0 million aggregate principal amount of its convertible senior note...
Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q3 2019 Earnings Call Nov 12, 2019 , 4:30 p.m. ET Operator Continue reading
Halozyme Therapeutics, Inc. (HALO) Q3 2019 Earnings Conference Call November 12, 2019 4:30 PM ET Company Participants Albert Kildani - Vice President of Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Laurie Stelzer - Chief Fin...
Gainers: CDLX +20.8% . TWOU +14.6% . DDOG +14.2% . VRAY +9.3% . NBRV +8.4% . More news on: Cardlytics, Inc., 2U, Inc., Datadog, Inc., Stocks on the move, Read more ...
MORRISVILLE, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial Organization (CCO), today announced the appointment of Bernadette Connaught...
Halozyme (NASDAQ: HALO ) Q3 results : More news on: Halozyme Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced that it intends to offer, subject to market conditions and other factors, $400...
Halozyme Therapeutics (NASDAQ: HALO ): Q3 GAAP EPS of -$0.17 misses by $0.05 . Revenue of $46.2M (+80.8% Y/Y) misses by $8.76M . Press Release More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...